Please login to the form below

Not currently logged in
Email:
Password:

Sobi wins European approval for oral form of orphan drug Orfadin

Expandstreatment options for rare genetic disease HT-1

Swedish Orphan Biovitrum (Sobi) 

The European Commission has approved an oral suspension formulation of Swedish Orphan Biovitrum's (Sobi) Orfadin (nitisinone).

The orphan drug treats the rare genetic disease Hereditary Tyrosinaemia type-1 (HT-1), a potentially fatal condition that affects infants and children and can result in liver and kidney failure if untreated.

Sobi's chief medical officer Birgitte Volck said: "The European Medicines Agency has called for more child-friendly formulations and the new oral suspension formulation is a demonstration of Sobi's commitment to the needs of the infants and children diagnosed with HT-1 early in life.

"An oral suspension of Orfadin for paediatric use will facilitate accurate dosing for infants and small children, and contribute to improving quality of life for patients and caregivers."

Orfadin works by blocking the breakdown of tyrosine to reduce the amount of toxic by-products in the body that can cause liver failure, renal dysfunction and neurological complications.

The drug was first approved in 2005 in a capsule formulation, in combination with dietary restriction of tyrosine and phenylalanine, to treat HT-1, which just 1,000 persons have been identified as living with today.

Last year sales of Orfadin rose by almost 50% to bring in SEK 547.9m and Sobi plans to launch the drug's new formulation in the second half of this year.

29th June 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics